Vor Biopharma VOR Proceeds From Issuance Of Common Stock From Underwritten Public Offering Net Of Underwriting Discount And Commissions
Proceeds From Issuance Of Common Stock From Underwritten Public Offering Net Of Underwriting Discount And Commissions at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept vor:ProceedsFromIssuanceOfCommonStockFromUnderwrittenPublicOfferingNetOfUnderwritingDiscountAndCommissions.
The official record: Vor Biopharma’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vor Biopharma's proceeds from issuance of common stock from underwritten public offering net of underwriting discount and commissions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vor Biopharma's proceeds from issuance of common stock from underwritten public offering net of underwriting discount and commissions?
- Vor Biopharma (VOR) reported proceeds from issuance of common stock from underwritten public offering net of underwriting discount and commissions of $27.03M in Q4 2025.
- What does proceeds from issuance of common stock from underwritten public offering net of underwriting discount and commissions mean?
- This measures the net cash proceeds received from public equity offerings after accounting for underwriting discounts and commissions. It highlights the company's success in accessing public capital markets to support long-term clinical programs.